MNKD Similar Chart Price Prediction
The price of MNKD is predicted to go up 51.93%, based on the high correlation periods with VC. The similarity of these two price pattern on the periods is 96.01%.
MNKD
VC
Up: 51.93%Similarity: 96.01%
MNKD Revenue Forecast
MNKD EPS Forecast
MNKD FAQs
What is MNKD revenue forecast for next quarter？
MNKD Analyst's Forecast
Tiago Fauth
Wells Fargo
Buy
2024-12-20
Price Target
$9
Upside
+31.39%
Wells Fargo initiated coverage of MannKind with an Overweight rating and $9 price target. The company's singular focus on the commercial business overlooks its two clinical stage programs with "derisked mechanisms" in a proven delivery technology that may enable better safety and tolerability in fairly substantial markets, the analyst tells investors in a research note. The firm sees the stock becoming a MNKD-101 and MKND-201 story in 2025 and 2026. MNKD-101 in lung disease and MNKD-201 in idiopathic pulmonary fibrosis are "under the radar programs with potential opportunities that are multiples of what the current base business is generating today, and these assets are worth a look," contends Wells.
Gregory Renza
RBC Capital
Hold → Buy
2024-12-19
Price Target
$7 → $10
Upside
+58.73%
